Ying Song

Prof. Ying Song

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2023 in BMC Cancer
Verified
Journal Article
Open access
PDF file
YWYue Wang
Yue Wang
ZGZheng Guo
Zheng Guo
YTYueli Tian
Yueli Tian
LCLiang Cong
Liang Cong
YZYulu Zheng
Yulu Zheng
YSYing Song
Ying Song
Background: The Mitogen-activated protein kinase 1 (MAPK1) has both independent functions of phosphorylating histones as a kinase and directly binding the promoter regions of genes to regulate gene expression as a transcription factor. Previous studies have identified elevated expression of MAPK1 in human gastric cancer, which is associated with its role as a kinase, facilitating the migration and invasion of gastric cancer cells. However, how MAPK1 binds to its target genes as a transcription factor and whether it modulates related gene expressions in gastric cancer remains unclear. Results: Here, we integrated biochemical assays (protein interactions and chromatin immunoprecipitation (ChIP)), cellular analysis assays (cell proliferation and migration), RNA sequencing, ChIP sequencing, and clinical analysis to investigate the potential genomic recognition patterns of MAPK1 in a human gastric adenocarcinoma cell-line (AGS) and to uncover its regulatory effect on gastric cancer progression. We confirmed that MAPK1 promotes AGS cells invasion and migration by regulating the target genes in different directions, up-regulating seven target genes (KRT13, KRT6A, KRT81, MYH15, STARD4, SYTL4, and TMEM267) and down-regulating one gene (FGG). Among them, five genes (FGG, MYH15, STARD4, SYTL4, and TMEM267) were first associated with cancer procession, while the other three (KRT81, KRT6A, and KRT13) have previously been confirmed to be related to cancer metastasis and migration. Conclusion: Our data showed that MAPK1 can bind to the promoter regions of these target genes to control their transcription as a bidirectional transcription factor, promoting AGS cell motility and invasion. Our research has expanded the understanding of the regulatory roles of MAPK1, enriched our knowledge of transcription factors, and provided novel candidates for cancer therapeutics.

26 November 2023 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
SLShan Lu
Shan Lu
Ruifeng DuanRuifeng Duan
Ruifeng Duan
LCLiang Cong
Liang Cong
YSYing Song
Ying Song
Gastric cancer (GC) has emerged as a significant issue in public health all worldwide as a result of its high mortality rate and dismal prognosis. AT-rich interactive domain 1 A (ARID1A) is a vital component of the switch/sucrose-non-fermentable (SWI/SNF) chromatin remodeling complex, and ARID1A mutations occur in various tumors, leading to protein loss and decreased expression; it then affects the tumor biological behavior or prognosis. More significantly, ARID1A mutations will likely be biological markers for immune checkpoint blockade (ICB) treatment and selective targeted therapy. To provide theoretical support for future research on the stratification of individuals with gastric cancer with ARID1A as a biomarker to achieve precision therapy, we have focused on the clinical significance, predictive value, underlying mechanisms, and possible treatment strategies for ARID1A mutations in gastric cancer in this review.

1 June 2018 in Chemico-Biological Interactions
Verified
Journal Article
Closed access
ljwei@jlu.edu.cnLijuan Weiljwei@jlu.edu.cnLijuan Wei
ljwei@jlu.edu.cnLijuan Wei
JLJun-An Li
Jun-An Li
DBDong-Mei Bai
Dong-Mei Bai
YSYing Song
Ying Song

5 September 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
JWJincheng Wang
Jincheng Wang
KZKun Zhang
Kun Zhang
TLTianzhou Liu
Tianzhou Liu
YSYing Song
Ying Song
PHPeiyan Hua
Peiyan Hua
YZYinghao Zhao
Yinghao Zhao
Objective: The progress of neoadjuvant therapy for resectable locally advanced esophageal cancer has been stagnant. There has been much progress in immunotherapy for advanced esophageal cancer, but the efficacy and safety of neoadjuvant immunotherapy for resectable locally advanced esophageal cancer have not yet been definitively demonstrated.Methods: Original articles describing the safety and efficacy of neoadjuvant immunotherapy in resectable locally advanced esophagus published until July 2022 were retrieved from PubMed, Embase, and the Cochrane Library. The ratio (OR) and 95% confidence interval (CI) were calculated to conduct heterogeneity and subgroup analysis.Results: In total, 759 patients from 21 studies were enrolled. The effectiveness of neoadjuvant immunotherapy in combination with chemotherapy was evaluated using the major pathologic response (MPR) and pathologic complete response (PCR). In the enrolled patients, 677 were treated surgically and 664 achieved R0 resection. Major pathological remission was achieved in 52.0% (95% CI: 0.44–0.57) of patients on neoadjuvant immunotherapy combined with chemotherapy and complete pathological remission in 29.5% (95% CI: 0.25–0.32) of patients. The safety was primarily assessed by the incidence of treatment-related adverse events (TRAEs) and surgical resection rates. The incidence of TRAEs and the surgical resection rate combined ORs were 0.15 (95% CI: 0.09–0.22) and 0.86 (95% CI: 0.83–0.89), respectively.Conclusion: Neoadjuvant immunotherapy combined with chemotherapy in locally advanced resectable esophageal cancer is effective and safe.

16 July 2020 in PeerJ
Verified
Journal Article
Open access
PDF file
XYXiaolin Yang
Xiaolin Yang
HSHongzhi Sun
Hongzhi Sun
YSYing Song
Ying Song
LYLi Yang
Li Yang
HLHaibo Liu
Haibo Liu
Background: Spindle pole body component 25 (SPC25) plays a vital role in many cellular processes, such as tumorigenesis. However, the clinical significance of SPC25 in hepatocellular carcinoma (HCC) has not been investigated. This study aimed to explore the expression patterns of SPC25 in HCC and non-neoplastic tissues and to investigate the diagnostic and prognostic values of SPC25. Method: The expression of SPC25 was examined in 374 HCC issues and 50 non-neoplastic tissues from The Cancer Genome Atlas (TCGA) cohort. The diagnostic and prognostic values of SPC25 were analyzed via receiver operating characteristic (ROC) curve and survival analyses, respectively. Univariate and multivariate Cox regression analyses were used to identify the prognostic factors and to establish a nomogram. The diagnostic and prognostic values were further validated in an external cohort from the International Cancer Genome Consortium (ICGC) database. Results: The expression of SPC25 in HCC tissues was significantly higher than that in normal tissues in both cohorts (all P < 0.001). The ROC curve analysis indicated that SPC25 expression has high diagnostic value in HCC with area under the curve (AUC) value of 0.969 (95% confidence interval [CI] [0.948–0.984]) and 0.945 (95% CI [0.920–0.965]) for TCGA and ICGC cohorts, respectively. Patients with HCC exhibiting high SPC25 expression were associated with worse prognosis than those exhibiting low SPC25 expression in both cohorts (all P < 0.001). SPC25 was independently associated with overall survival in both cohorts (all P < 0.001). The concordance indices of the nomogram for predicting overall survival in TCGA and ICGC cohorts were 0.647 and 0.805, respectively, which were higher than those of the American Joint Committee on Cancer (AJCC) staging system. Conclusion: SPC25 was upregulated in HCC and independently predicted poor overall survival of patients with HCC. Therefore, SPC25 is an effective diagnostic and prognostic biomarker for HCC. An SPC25-based nomogram was more accurate and useful than the AJCC staging system to predict prognosis of HCC.

2 March 2025 in Health Science Reports
Verified
Journal Article
Open access
SLShan Lu
Shan Lu
YZYahong Zhu
Yahong Zhu
MCMingyu Cui
Mingyu Cui
ZGZheng Guo
Zheng Guo
XLXingang Li
Xingang Li
YSYing Song
Ying Song
Background and Aims: Gastroesophageal reflux disease (GERD) is common worldwide. Although associations between sedentary behaviour (LSBs), physical activity (PAs), and GERD have been reported, their causal relationships remain unclear. This study uses Mendelian randomization (MR) to examine these associations with GERD.Methods: Genetic instruments from the UK Biobank and other consortia were utilized to assess the causal relationship between LSBs, PAs, and GERD. Causal analyses employed inverse variance weighted (IVW), weighted‐median (WM), and MR‐Egger regression. Sensitivity analyses included Cochran's Q test, MR‐Egger intercept test, leave‐one‐out analysis, and funnel plot assessment. Outliers were detected using MR‐PRESSO and Radial MR. A risk factor analysis explored potential causal links.Results: Genetically predicted leisure television (TV) watching (OR = 2.29, 95% CI 2.12–2.48; p < 0.001) and self‐reported moderate physical activity (MPAs) (OR = 2.45, 95% CI 1.46–4.13; p < 0.001) were associated with an higher risk of GERD. In contrast, leisure computer use (OR = 0.62, 95% CI 0.53–0.73; p < 0.001) and accelerometer‐measured fractional accelerations > 425 milligravities (OR = 0.68, 95% CI 0.52–0.88; p = 0.003) were associated with a lower risk of GERD. No causal relationship was observed between driving, self‐reported vigorous physical activities (VPAs), and accelerometer‐measured “average acceleration” with GERD. Risk factor analyses suggested that metabolic risk factors, such as smoking, high body mass index, elevated serum triglyceride levels, insulin resistance, and type 2 diabetes might mediate the observed causal links.Conclusions: Leisure TV watching and self‐reported MPA are associated with an higher risk of GERD, whereas leisure computer use and accelerometer‐measured fractional acceleration > 425 milligravities may serve as protective factors against GERD. These findings highlight the necessity of differentiating various LSBs and PAs in GERD research.